1	A risk stratification model for high-flow nasal cannula use in patients with coronavirus disease
2	2019 in Japan: a single-center retrospective observational cohort study
3	
4	Short title: A risk stratification model for severe COVID-19
5	
6	Ibuki Kurihara <sup>1*</sup> and Hitoshi Sugawara <sup>1</sup>
7	
8	<sup>1</sup> Division of General Medicine, Department of Comprehensive Medicine 1, Saitama Medical Center,
9	Jichi Medical University, Saitama City, Saitama, Japan
10	
11	* Corresponding author:
12	Ibuki Kurihara
13	Department of General Medicine, Saitama Medical Center, Jichi Medical University

1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama, 330-8503, Japan

Tel: +81-48-647-2111; Fax: +81-48-644-8617; E-mail address: hsmdfacp@jichi.ac.jp

14

15

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

**Abstract Background:** The coronavirus disease 2019 (COVID-19) pandemic has put a strain on the healthcare system, and sudden changes in disease status during home treatment have become a serious issue. Therefore, prediction of disease severity and allocation of sufficient medical resources. including high-flow nasal cannula (HFNC), to patients in need are important. We aimed to determine risk factors for the need of HFNC use in COVID-19. **Methods:** This was a single-center retrospective observational cohort study including all eligible hospitalized adult patients aged ≥18 years diagnosed with COVID-19 between April 14, 2020 and August 5, 2021 who were treated in the study hospital. The primary outcome was critical respiratory illness meeting one of the following criteria: oxygenation flow rate > 10 L/min, high-flow oxygenation, noninvasive ventilation, invasive ventilation, and death. Nineteen potential predictive variables, including patient characteristics at hospital admission, were screened using least absolute shrinkage and selection operator and logistic regression to construct a predictive risk score. Accuracy of the risk score was determined using area under the receiver operating characteristic curve. **Results:** The study cohort included 148 patients. The rate of critical respiratory illness was 22.9% (all patients needed high-flow device support). Among the 19 potential variables, percutaneous oxygen saturation (SpO<sub>2</sub>) <92% (odds ratio [OR] 7.50, 95% confidence interval [CI] 2.806–20.82) and IL-6 (OR 1.021, 95% CI 1.010–1.033) were included in developing the risk score, which was termed interleukin (IL)-6-based COVID-19 severity (IBC-S) score. Conclusions: The IBC-S score, an easy-to-use risk score based on parameters available at the time of hospital admission, predicted critical respiratory failure in patients with COVID-19. In primary care settings, the IBC-S score based on interleukin-6 and SpO2 might aid in determining patients

who should be transported to a tertiary medical institution or an isolation facility.

Introduction

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

The coronavirus disease 2019 (COVID-19) pandemic has claimed approximately 15 million lives as of September 2022 [1]. While approximately 80% of patients with COVID-19 experience a mild disease course and recover, the remaining 20% of the infected patients rapidly progress to severe COVID-19 [2] High-flow nasal cannula (HFNC) can deliver high concentrations of humidified oxygen with low positive end-expiratory pressure and facilitate the elimination of carbon dioxide, thereby rapidly relieving the symptoms of acute hypoxemic respiratory failure [3]. In the COVID-19 pandemic, HFNC use significantly reduced the need for mechanical ventilation support and shortened the time to clinical recovery compared with conventional low-flow oxygen therapy [4]; therefore, HFNC has been played an important role in the management of patients with severe or critical COVID-19 [5]. However, HFNC uses hyperbaric oxygen, which limits the medical facilities that can utilize it. In Japan, the COVID-19 pandemic has put a strain on the healthcare system and the sudden change in disease status during home treatment has become a serious problem [6]. Therefore, predicting the severity of COVID-19 and allocating sufficient medical resources, including HFNC, to patients in need are important. Therefore, we aimed to determine the risk factors for HFNC use in patients with COVID-19 by examining the medical records of patients treated in our medical center during the COVID-19 Alpha, Beta, and Delta surges in Japan.

### **Materials and Methods**

### Study design, participants, and setting

This was a single-center retrospective observational cohort study including all adult patients aged ≥18 years that were diagnosed with COVID-19 and hospitalized in the Division of General Medicine, Saitama Medical Center, Jichi Medical University between April 14, 2020 and August 5, 2021. The study period covered the COVID-19 Alpha, Beta, and Delta surges in Japan.

Primary outcome, data collection, and processing The primary outcome was critical respiratory illness meeting one of the following criteria any time after the day of admission: oxygenation flow rate ≥10 L/min, high-flow oxygenation, noninvasive ventilation, invasive ventilation, and death [7]. In all patients, the COVID-19 diagnosis was confirmed based on a positive nucleic acid amplification test using oropharyngeal, nasopharyngeal, or oropharyngeal/nasopharyngeal swab samples. The study data were collected from electronic medical records between September 15, 2021 and March 31, 2023. Sample size estimation G\*Power version 3.1.9.2 (Heinrich Heine University Duesseldorf, Duesseldorf, Germany) was used to determine the required sample size using the following parameters; test family, z test; statistical test, logistic regression; type of power analysis, a priori: compute required sample size—given α, power, and effect size; tails, two; odds ratio, 8.142 (alternative hypothesis was assumed to be moderately correlated at 0.3, and null hypothesis was assumed to be 0.05);  $\alpha$  error probability, 0.05; power  $(1 - \beta)$  error probability, 0.8;  $R^2$  other X, 0.26 (i.e., the regression equation is accurate.); X distribution, exponential; X parm  $\lambda$ , 0.3. The calculated sample size was 44. Potential predictive variables We referred to the previous studies and extracted potential predictive variables [2,8,9]. Potential predictive variables were patient characteristics at the time of hospital admission and included demographic variables (age, sex, and smoking status), medical history (diabetes mellitus, hypertension, coronary artery disease, chronic kidney disease, chronic heart failure, and cancer), physical parameters (body mass index and percutaneous oxygen saturation [SpO<sub>2</sub>]), laboratory parameters (lymphocyte count, C-reactive protein, albumin, direct bilirubin, lactate dehydrogenase, ferritin, D-dimer, and interleukin 6 [IL-6]), and prehospital treatments (steroid, remdesivir,

### **Ethics** approval

tocilizumab, and baricitinib).

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

The current study was approved by the Institutional Clinical Review Board of Saitama Medical Center, Jichi Medical University (approval no: Clinical # S21-024). In accordance with the ethical guidelines for medical and health research involving human subjects in Japan, written informed consent was not required due to the retrospective study design. The study was conducted with the online opt-out method accessed through the hospital website.

## **Statistical analysis**

The 19 potential predictive variables were entered into analysis to construct a predictive risk score for HFNC use. The Mann–Whitney U and Pearson's chi-square tests were used to compare continuous and categorical baseline characteristics, respectively. The least absolute shrinkage and selection operator method was used to minimize the potential collinearity of variables from the same patient and the over-fitting of variables. Imputation for missing variables was considered if missing values were lower than 20%. The selected variables and treatment before admission which was a confounder, were included in the multiple logistic regression analysis. The predictive value of risk stratification models was assessed using area under the receiver operating characteristic curve. For continuous variables included in the model, parameter values with the equal sensitivity and specificity and the highest positive predictive value were chosen as cut-off values [10]. After the creation of the risk scoring model using the selected variables, bootstrapped logistic regression was used to verify internal validity. All statistical tests were two-tailed with significance set at a P value of <0.05.

The Stata/SE 16.2 software (StataCorp, College Station, TX, USA) was used for all statistical analyses.

## **Results**

### **Baseline information of the participants**

The study flow chart is shown in Fig 1. During the study period, a total of 152 patients were admitted with COVID-19 in the study institution. The actual study cohort size was markedly above the estimated sample size (152 versus 44), which increased the power of the study. Of these 152 patients, 4 patients who met the primary study endpoint of critical respiratory illness on the day of admission were excluded; therefore, the final analysis included 148 patients.

Fig 1 Study flow diagram

PCO; primary composite outcome; COVID-19, coronavirus disease 2019

Table 1 shows the demographic and clinical characteristics of the cohort. Briefly, the median age (interquartile range) was 58.5 (23–84) years, 43 patients (30%) of the patients were female, and 18.4% of the patients had at least one comorbidity. Of the 148 patients, 34 patients (22.9%) required oxygen with a flow rate of  $\geq$ 10 L/min, 34 patients (22.9%) required high-flow device support, 9 (6.1%) patients required invasive ventilation, and 13 patients (8.8%) died. Additionally, 12 patients (8.1%) were admitted to the intensive care unit after the day of admission.

Table 1. Baseline patient characteristics

Total patients (n = 148)		Out	Non-outcome (n = 114)	P
		Outcome (n = 34)		value
Age	58.5 (23–84)	60 (44–89)	57.5 (22–83)	0.037
Male, n (%)	105 (70%)	25 (73.5%)	80 (70.1%)	0.705
BMI (kg/m²)	24.69 (17.9–33.5)	25.1 (16.8–33.3)	24.6 (17.9–33.8)	0.521
Diabetes, n (%)	51 (34.4%)	18 (52.9%)	33 (28.9%)	0.01

Hypertension, n (%)	77 (52.0%)	25 (73%)	52 (45.6%)	0.004
Ever smoker, n (%)	71 (48.3%)	14 (41.1%)	57 (50.4%)	0.343
Coronary artery disease, n (%)	11 (7.4%)	4 (11.7%)	7 (6.1%)	0.272
Chronic heart failure, n (%)	6 (4.0%)	3 (8.8%)	3 (2.6%)	0.108
Chronic kidney disease, n (%)	16 (10.8%)	4 (11.76%)	12 (10.5%)	0.838
SpO <sub>2</sub> on room air <92%, n (%)	70 (47.3%)	28 (82.3%)	42 (36.8%)	0
Malignancy, n (%)	28 (18.9%)	6 (17.6%)	22 (19.3%)	0.829
Laboratory tests				
Albumin (g/dL)	3.6 (2.5–4.5)	3.4 (1.9–4)	3.7 (2.6–4.5)	0.001
D-bil (mg/dL)	0.2 (0.1–0.64)	0.24 (0.12–0.87)	0.19 (0.1–0.55)	0.029
LDH (U/L)	296 (146–541)	358 (214–591)	264 (143–541)	0
CRP (mg/dL)	3.95 (0.09–20.14)	7.65 (0.76–29.2)	2.94 (0.06–14.2)	0
Lymphocyte(/μL)	804 (294–1938)	516 (172–1286)	891 (392–2172)	0
Ferritin (ng/mL)	359 (60–1486)	467 (139–1769)	310 (51–1486)	0.014
D-dimer (μg/mL)	1.15 (1–4.8)	1.4 (1–5.1)	1.1 (1–4.8)	0.038
IL-6 (pg/mL)	15 (2.2–139)	31.7 (5.6–186)	13.05 (1.3–65.5)	0
Therapy before-admission				
Steroids, n (%)	25 (16.8%)	10 (29.41%)	15 (13.16%)	0.026

It is made available under a	CC-B	Y 4.0 International license.
------------------------------	------	------------------------------

Remdesivir, n (%)	6 (4.0%)	4 (3.5%)	2 (5.88%)	0.538
Tocilizumab, n (%)	0	0	0	
Baricitinib, n (%)	1 (0.68%)	1 (0.88%)	0 (0.0%)	0.534

Continuous data are shown as medians with interquartile ranges.

The Mann-Whitney and Pearson's chi-square tests were used.

BMI, body mass index; SpO<sub>2</sub>, oxygen saturation; D-bil, direct bilirubin; LDH, lactate dehydrogenase; CRP,

C-reactive protein; IL-6, interleukin-6

### **Selection of predictors**

130

131

132

133

134

135

136

137

138

A total of 19 variables that were measured at the time of admission were included in the least absolute shrinkage and selection operator regression, which identified SpO<sub>2</sub> and IL-6 as significant predictors of critical respiratory illness. In the logistic regression model including these two parameters, both an SpO<sub>2</sub> <92% (odds ratio [OR] 7.50, 95% confidence interval [CI] 2.806–20.82; P < 0.001) and IL-6 (per 10 pg/ml increase, OR 1.23, 95% CI 1.010–1.038; P < 0.001) were independent and significant predictors of critical respiratory illness and were included in the risk score (Table 2).

Table 2 Association of SpO2 <92% and IL-6 with the risk of critical respiratory illness

Crude		Multivariable-adjusted	
OR (95% CI)	P value	OR (95% CI)	P value

SpO <sub>2</sub> <92%	8.00 (3.06–20.9)	< 0.001	7.50 (2.80–20.0)	< 0.001
IL-6 (per 10 pg/mL increase)	1.19 (1.07–1.32)	0.001	1.23 (1.10–1.38)	< 0.001

Logistic regression models were used to estimate odds ratios, 95% confidence intervals, and P values.

The multivariable logistic regression model included two likely confounders: before-admission therapy with steroids and remdesivir.

SpO<sub>2</sub>, oxygen saturation; IL-6, interleukin-6; CI, confidence interval; OR, odds ratio

# Construction of the risk score

139

140

141

142

143

144

The cut-off IL-6 value of 19.5 pg/mL exhibited equal sensitivity and specificity with the highest positive predictive value of 63.2 pg/mL; therefore, this value was used to create the IL-6-based COVID-19 severity [IBC-S] score to determine the risk of critical respiratory failure (Table 3). The IBC-S risk score ranged from 0 to 3.

Table 3 IL-6 based COVID-19 severity score to predict the critical respiratory illness

Variable	IBC-S score
SpO <sub>2</sub> on room air (%)	
≥92	0
<92	1
IL-6 (pg/mL)	
<19.5	0

19.5–63.2	1
63.2	2

IBC-S, interleukin-6-based COVID-19 severity; SpO<sub>2</sub>, oxygen saturation; IL-6, interleukin-6.

### Performance of the risk score

The bootstrap analysis for internal validation indicated that the mean area under the receiver operating characteristic curve based on the cohort data was 0.834 (OR 4.762, 95% CI 2.198–10.31; P < 0.001). An IBC-S score of <1 had a sensitivity of 93.94% and a negative likelihood ratio of 0.13. An IBC-S score of >3 had a specificity of 98.15% and a positive likelihood ratio of 19.63 (Table 4).

Table 4 Performance of the IBC-S score

Cut-off value	Sensitivity (%)	Specificity (%)	Positive likelihood ratio	Negative likelihood ratio
≤1	93.9	43.5	1.66	0.13
≥3	36.3	98.1	19.6	0.64

## **Discussion**

Early identification of patients with COVID-19 at increased risk for HFNC use is beneficial for the proper use of medical resources. In the present study, we found that the combination of SpO<sub>2</sub> and IL-6 at admission may predict critical respiratory illness in patients hospitalized with COVID-19.

Simple risk scoring strategies are important in primary care settings. The IBC-S score provides a simple assessment approach based on a small number of predictor variables determined at the time of admission. The IBC-S score has only two predictor variables; in comparison, the 4C

mortality score has eight predictor variables and the COVID-GRAM score has ten predictor variables [2,11]. Moreover, the IBC-S score requires only physical examination findings and the measurement of IL-6 and does not require medical history, blood gas tests, or imaging studies. In the COVID-19 era, simple risk scores are important since imaging studies and more sophisticated tests may not be available in many situations.

SpO<sub>2</sub> is one of the two variables of the IBC-S score. The main pathologic feature of COVID-19 is viral pneumonia with alveolar edema and blockage of small bronchi, leading to the compromise of pulmonary gas exchange and reduced oxygen saturation, which is a major indicator of disease severity [12]. Since arterial blood gas analysis is an invasive and complex test, SpO<sub>2</sub> measurement is more frequently used to estimate the arterial oxygen partial pressure in primary care settings [13]. A study previously reported SpO<sub>2</sub> as one of the predictors of inpatient mortality in patients with COVID-19 [12]. SpO<sub>2</sub> is one of the preeminent predictors of severe COVID-19.

High IL-6 levels are a predictor of severe COVID-19. IL-6 is a cytokine in cell signaling and the regulation of immune cells. IL-6 has a strong proinflammatory effect with multiple biologic functions and plays an important role in inflammation [14]. In patients with COVID-19 complicated by acute respiratory distress syndrome, hyperactivation of the immune system with prominent IL-6 response can lead to organ dysfunction [9]. Several systematic reviews and meta-analyses revealed that IL-6 inhibitors such as tocilizumab were associated with reduced mortality in patients with COVID-19 [9,15]. In one systematic review and meta-analysis [9,15], IL-6 was one of the predictors of ventilator management and death [9,15][NO\_PRINTED\_FORM]. In primary care settings, the evaluation of IL-6 and SpO<sub>2</sub> may aid in identifying patients who should be transported to an appropriate medical institution or an isolation facility.

The present study has several limitations that should be acknowledged. First, the external validity of the IBC-S score was not tested and future studies using other cohorts are warranted to confirm its validity. Second, the study population did not include patients infected with the Omicron

variants, which have been increasing in prevalence worldwide [16]. Several Omicron subvariants exhibit replication advantage over prior variants [17] and can evade human immunity to a greater extent than the prior variants [18]. Additionally, the Omicron subvariants might be associated with less severe disease than the other variants [19]. Zhang et al. reported that an SpO<sub>2</sub> of <90% was associated with critical illness in [20] patients infected with the Omicron variant, although the association of IL-6 with disease severity was not investigated [20]. It is possible that the IBC-S score might show different results in the evaluation of patients infected with the Omicron variant. Finally, the current study cohort did not include patients who were vaccinated. Future studies should consider evaluating the utility of the IBC-S score in other cohorts including those infected with other variants and those who are vaccinated. .

### **Conclusions**

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

205

206

The IBC-S score, an easy-to-use risk score based on parameters that can be obtained at the time of hospital admission, predicted critical respiratory failure. In primary care settings, the evaluation of IL-6 and SpO<sub>2</sub> might aid in determining patients who should be transported to a tertiary medical institution or an isolation facility.

### List of abbreviations

- 202 COVID-19, coronavirus disease 2019
- 203 HFNC, high-flow nasal cannula
- 204 SpO<sub>2</sub>, percutaneous oxygen saturation

# Acknowledgments

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

We would like to thank Drs. Takahiko Fukuchi, Hiroshi Hori, and Hanako Yoshihara for their medical care of the study participants. We also thank Enago for providing English proofreading services. References 1. Barouch DH. Covid-19 vaccines — immunity, variants, boosters. N Engl J Med. 2022;387: 1011-1020. doi: 10.1056/NEJMra2206573. 2. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: Development and validation of the 4C mortality score. BMJ. 2020;370: m3339. doi: 10.1136/bmj.m3339. 3. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372: 2185-2196. doi: 10.1056/NEJMoa1503326. 4. Ospina-Tascón GA, Calderón-Tapia LE, García AF, Zarama V, Gómez-Álvarez F, Álvarez-Saa T, et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: A randomized clinical trial. JAMA. 2021;326: 2161-2171. doi:

10.1001/jama.2021.20714.

- Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ. Rational use of face masks in the COVID-19 pandemic. Vol. 8, In: The lancet respiratory medicine. London: Lancet Publishing Group; 2020. pp. 434-436. doi: 10.1016/S2213-2600(20)30134-X.
   Terada M, Ohtsu H, Saito S, Havakawa K, Tsuzuki S, Asai Y, et al. Risk factors for
- 6. Terada M, Ohtsu H, Saito S, Hayakawa K, Tsuzuki S, Asai Y, et al. Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. BMJ Open. 2021;11: e047007. doi: 10.1136/bmjopen-2020-047007.
- 7. Haimovich AD, Ravindra NG, Stoytchev S, Young HP, Wilson FP, van Dijk D, et al.

  Development and validation of the quick COVID-19 severity index: A prognostic tool

  for early clinical decompensation. Ann Emerg Med. 2020;76: 442-453. doi:

  10.1016/j.annemergmed.2020.07.022.
- 8. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180: 1081-1089. doi: 10.1001/jamainternmed.2020.2033.
- 9. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Vol. 30, In: Reviews in medical virology. New York: John Wiley and Sons Ltd; 2020. pp. 1-9. doi: 10.1002/rmv.2141.

10. Saito K, Sugawara H, Ichihara K, Watanabe T, Ishii A, Fukuchi T. Prediction of 24472-hour mortality in patients with extremely high serum C-reactive protein levels using 245a novel weighted average of risk scores. PLoS One. 2021;16: e0246259. doi: 24610.1371/journal.pone.0246259. 24724811. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients 249with COVID-19. JAMA Intern Med. 2020;180: 1081-1089. doi: 25010.1001/jamainternmed.2020.2033. 25125212. Xie J, Hungerford D, Chen H, Abrams ST, Li S, Wang G, et al. Development and external validation of a prognostic multivariable model on admission for hospitalized 253patients with COVID-19. SSRN J. doi: 10.2139/ssrn.3562456. 254 13. Seifi S, Khatony A, Moradi G, Abdi A, Najafi F. Accuracy of pulse oximetry in 255 256detection of oxygen saturation in patients admitted to the intensive care unit of heart surgery: Comparison of finger, toe, forehead and earlobe probes. BMC Nurs. 2018;17: 25715. doi: 10.1186/s12912-018-0283-1. 25814. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between 259inflammation and cancer. Vol. 26, In: Seminars in immunology. USA: Academic Press: 260

2014. pp. 54-74. doi: 10.1016/j.smim.2014.01.001.

263

264

265

266

267

268

269

270

271

272

273

274

275


276

277

278

15. Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;3: CD013881. 16. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28: 1785-1790. doi: 10.1038/s41591-022-01911-2. Baker JM, Nakayama JY, O'hegarty M, Mcgowan A, Teran RA, Bart SM, et al. 17. Morbidity and mortality weekly report SARS-CoV-2 B.1.1.529 (Omicron) variant transmission within households-four U.S. Jurisdictions, 2022 [cited 2021 Nov]. Available from: https://www.cdc.gov/mmwr 18. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of omicron in South Africa. Science. 2022;376: eabn4947. doi: 10.1126/science.abn4947. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. 19. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study. Lancet. 2022;399: 1303-1312. doi: 10.1016/S0140-6736(22)00462-7.

20. Ebell MH, Hamadani R, Kieber-Emmons A. Development and validation of simple risk scores to predict hospitalization in outpatients with COVID-19 including the omicron variant. J Am Board Fam Med. 2022;35: 1058-1064. doi: 10.3122/jabfm.2022.220056R1.



Figure